image
Healthcare - Biotechnology - NASDAQ - US
$ 6.39
-5.11 %
$ 42.1 M
Market Cap
-0.52
P/E
CASH FLOW STATEMENT
-30.7 M OPERATING CASH FLOW
-7.10%
-36 M INVESTING CASH FLOW
-76580.85%
51.9 M FINANCING CASH FLOW
110.08%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Forte Biosciences, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -35.5 M
Depreciation & Amortization 39 K
Capital Expenditures -37 K
Stock-Based Compensation 3.1 M
Change in Working Capital 1.76 M
Others -1.42 M
Free Cash Flow -30.8 M

Cash Flow

Millions
Dec-2024 Dec-2023 Dec-2022 Dec-2021 Dec-2020 Dec-2019 Dec-2018 Dec-2017 Dec-2016 Dec-2015
OPERATING CASH FLOW
Net Income (35.5) (31.5) (13.9) (21.7) (46.5) (4.1) (49.0) (38.9) (33.5) (23.1)
Depreciation & Amortization 39 K 9 K 0 36 K 54 K 11 K 0.6 0.3 0.3 0.2
Deferred Income Tax 0 0 0 0 0 0.9 (6.9) (4.5) 0 0
Stock Based Compensation 3.1 3.3 4.0 4.2 1.0 35.7 K 6.9 4.5 0 0
Other Operating Activities (0.2) (0.1) 3.8 61 K 30.9 (0.9) 7.8 5.3 1.7 0.9
Change in Working Capital 1.8 (0.4) 1.7 0.7 (3.8) 1.3 6.1 2.5 1.9 0.7
Cash From Operations (30.7) (28.7) (8.2) (16.7) (18.4) (2.8) (34.5) (31.1) (29.5) (21.0)
INVESTING CASH FLOW
Capital Expenditures 37 K 88 K 0 0 0 (0.2) (2.0) (0.7) (0.5) (0.2)
Other Items (36.0) 0.1 0 0 3.6 0 (2.2) (27.1) 25.1 (24.7)
Cash From Investing Activities (36.0) 47 K 0 0 3.6 (0.2) (4.2) (27.7) 24.6 (24.9)
FINANCING CASH FLOW
Common Stock Repurchased 1 K 0 0 0 0 0 0 89 K 3.4 33.2
Total Debt Repaid 0 0 0 0 0 0 23.3 0.1 2.9 50.7
Dividends Paid 0 0 0 0 0 0 0 0 0 0
Other Financing Activities (1.1) 28 K 12 K 44 K 32 K 4.9 (8.6) 0 (0.6) (1.0)
Cash From Financing Activities 51.9 24.7 7.2 44 K 66.7 4.9 43.5 89.3 2.3 49.9
CHANGE IN CASH
Net Change In Cash (14.9) (4.0) (0.9) (16.7) 51.8 1.9 4.9 30.4 (2.6) 3.9
FREE CASH FLOW
Free Cash Flow (30.8) (28.8) (8.2) (16.7) (18.4) (2.9) (36.4) (31.8) (30.1) (21.3)